Literature DB >> 19644070

High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction.

Mitchell S V Elkind1, Vladimir Leon, Yeseon P Moon, Myunghee C Paik, Ralph L Sacco.   

Abstract

BACKGROUND AND
PURPOSE: High-sensitivity C-reactive protein (hsCRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2) are hypothesized to be biomarkers of systemic inflammation and risk of myocardial infarction (MI) and stroke. Little is known, however, about the stability of these markers over time, and in particular, about the effects of acute vascular events on these marker levels.
METHODS: Serum samples were collected at 4 annual intervals in 52 stroke-free participants from the Northern Manhattan Study (NOMAS) and assayed for hsCRP and Lp-PLA2 mass and activity levels using standard techniques. Log transformation of levels was performed as needed to stabilize the variance. Stability of marker levels over time was assessed using random effects models unadjusted and adjusted for demographics and other risk factors. In addition, samples from 37 initially stroke-free participants with stroke (n=17) or MI (n=20) were available for measurement before and after the vascular event (median 5 days, range 2 to 40 days). Levels before and after events were compared using nonparametric tests.
RESULTS: HsCRP and Lp-PLA2 activity levels were stable over time, whereas Lp-PLA2 mass levels decreased on average 5% per year (P=0.0015). Using accepted thresholds to define risk categories of Lp-PLA2 mass, there was no significant change over time. HsCRP increased after stroke (from median 2.2 mg/L prestroke to 6.5 mg/L poststroke; P=0.0067) and MI (from median 2.5 mg/L pre-MI to 13.5 mg/L post-MI; P<0.0001). Lp-PLA2 mass and activity levels both decreased significantly after stroke and MI (for Lp-PLA2 mass, from median 210.0 ng/mL to 169.4 ng/mL poststroke, P=0.0348, and from median 233.0 ng/mL to 153.9 post-MI, P<0.0001).
CONCLUSION: Lp-PLA2 mass levels decrease modestly, whereas hsCRP and Lp-PLA2 activity appear stable over time. Acutely after stroke and MI, hsCRP increases whereas Lp-PLA2 mass and activity levels decrease. These changes imply that measurements made soon after stroke and MI are not reflective of prestroke levels and may be less reliable for long-term risk stratification.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19644070      PMCID: PMC2761676          DOI: 10.1161/STROKEAHA.109.552802

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  22 in total

Review 1.  Inflammation, atherosclerosis, and stroke.

Authors:  Mitchell S V Elkind
Journal:  Neurologist       Date:  2006-05       Impact factor: 1.398

2.  Fluctuating inflammatory markers in patients with stable ischemic heart disease.

Authors:  Peter Bogaty; James M Brophy; Luce Boyer; Serge Simard; Lawrence Joseph; Fernand Bertrand; Gilles R Dagenais
Journal:  Arch Intern Med       Date:  2005-01-24

3.  Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study.

Authors:  Carlos Iribarren; Myron D Gross; Jeanne A Darbinian; David R Jacobs; Stephen Sidney; Catherine M Loria
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-10-21       Impact factor: 8.311

4.  The effect of statin therapy on lipoprotein associated phospholipase A2 levels.

Authors:  Michelle A Albert; Robert J Glynn; Robert L Wolfert; Paul M Ridker
Journal:  Atherosclerosis       Date:  2005-09       Impact factor: 5.162

Review 5.  Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members.

Authors:  Mario Di Napoli; Markus Schwaninger; Roberto Cappelli; Elena Ceccarelli; Giacinto Di Gianfilippo; Cristina Donati; Hedley C A Emsley; Sandro Forconi; Stephen J Hopkins; Luca Masotti; Keith W Muir; Anna Paciucci; Francesca Papa; Sabina Roncacci; Dirk Sander; Kerstin Sander; Craig J Smith; Alessandro Stefanini; Daniela Weber
Journal:  Stroke       Date:  2005-05-05       Impact factor: 7.914

Review 6.  Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults.

Authors:  Richard B Lanman; Robert L Wolfert; James K Fleming; Allan S Jaffe; William L Roberts; G Russell Warnick; Joseph P McConnell
Journal:  Prev Cardiol       Date:  2006

7.  Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.

Authors:  Hok-Hay S Oei; Irene M van der Meer; Albert Hofman; Peter J Koudstaal; Theo Stijnen; Monique M B Breteler; Jacqueline C M Witteman
Journal:  Circulation       Date:  2005-02-08       Impact factor: 29.690

8.  Lipid and lipoprotein levels remain stable in acute ischemic stroke: the Northern Manhattan Stroke Study.

Authors:  D E Kargman; C Tuck; L Berglund; I F Lin; R S Mukherjee; E V Thompson; J Jones; B Boden-Albala; M C Paik; R L Sacco
Journal:  Atherosclerosis       Date:  1998-08       Impact factor: 5.162

9.  Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.

Authors:  Michelle O'Donoghue; David A Morrow; Marc S Sabatine; Sabina A Murphy; Carolyn H McCabe; Christopher P Cannon; Eugene Braunwald
Journal:  Circulation       Date:  2006-03-14       Impact factor: 29.690

10.  The behavioral risk factor surveys: II. Design, methods, and estimates from combined state data.

Authors:  E M Gentry; W D Kalsbeek; G C Hogelin; J T Jones; K L Gaines; M R Forman; J S Marks; F L Trowbridge
Journal:  Am J Prev Med       Date:  1985 Nov-Dec       Impact factor: 5.043

View more
  17 in total

1.  Association of Lp-PLA2-A and early recurrence of vascular events after TIA and minor stroke.

Authors:  Jinxi Lin; Hongwei Zheng; Brett L Cucchiara; Jiejie Li; Xingquan Zhao; Xianhong Liang; Chunxue Wang; Hao Li; Michael T Mullen; S Claiborne Johnston; Yilong Wang; Yongjun Wang
Journal:  Neurology       Date:  2015-08-26       Impact factor: 9.910

Review 2.  Inflammatory mechanisms of stroke.

Authors:  Mitchell S V Elkind
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

3.  Molecular mechanisms underlying application of serum procalcitonin and stool miR-637 in prognosis of acute ischemic stroke.

Authors:  You-Mei Li; Xue-Yuan Liu
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

4.  Stroke in Women: What is Different?

Authors:  Dara G Jamieson; Maryna Skliut
Journal:  Curr Atheroscler Rep       Date:  2010-07       Impact factor: 5.113

5.  C-reactive protein as a prognostic marker after lacunar stroke: levels of inflammatory markers in the treatment of stroke study.

Authors:  Mitchell S V Elkind; Jorge M Luna; Leslie A McClure; Yu Zhang; Christopher S Coffey; Ana Roldan; Oscar H Del Brutto; Edwin Javier Pretell; L Creed Pettigrew; Brett C Meyer; Jorge Tapia; Carole White; Oscar R Benavente
Journal:  Stroke       Date:  2014-02-12       Impact factor: 7.914

6.  Therapeutic Options to Reduce Lp-PLA2 Levels and the Potential Impact on Vascular Risk Reduction.

Authors:  Koto Ishida; Brett Cucchiara
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-06

7.  Periodontal microbiota and phospholipases: the Oral Infections and Vascular Disease Epidemiology Study (INVEST).

Authors:  Adrien Boillot; Ryan T Demmer; Ziad Mallat; Ralph L Sacco; David R Jacobs; Joelle Benessiano; Alain Tedgui; Tatjana Rundek; Panos N Papapanou; Moïse Desvarieux
Journal:  Atherosclerosis       Date:  2015-07-22       Impact factor: 5.162

8.  Inflammatory biomarkers of vascular risk as correlates of leukoariosis.

Authors:  Clinton B Wright; Yeseon Moon; Myunghee C Paik; Truman R Brown; LeRoy Rabbani; Mitsuhiro Yoshita; Charles DeCarli; Ralph Sacco; Mitchell S V Elkind
Journal:  Stroke       Date:  2009-08-20       Impact factor: 7.914

9.  High-sensitivity C-reactive protein predicts mortality but not stroke: the Northern Manhattan Study.

Authors:  M S V Elkind; J M Luna; Y P Moon; K M Liu; S L Spitalnik; M C Paik; R L Sacco
Journal:  Neurology       Date:  2009-10-20       Impact factor: 9.910

10.  Relation between lipoprotein-associated phospholipase A2 mass and incident ischemic stroke severity.

Authors:  Feng Zhou; Yukai Liu; Hongchao Shi; Qing Huang; Junshan Zhou
Journal:  Neurol Sci       Date:  2018-06-25       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.